Q-omics provides the consensus-scored BLOC1S4 profile across patient tissues and cancer cell-line models. BLOC1S4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BLOC1S4 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, BLOC1S4 RNA expression shows 18,426 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where BLOC1S4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLOC1S4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLOC1S4 survival associations across molecular data types. BLOC1S4 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLOC1S4 RNA expression–survival associations across cancer types. High BLOC1S4 expression shows unfavorable associations in KIRP, LIHC, LUAD, UVM and LAML, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for BLOC1S4 RNA expression.
This table summarizes BLOC1S4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BLOC1S4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLOC1S4 shows higher tumor expression in KIRC, HNSC, LIHC, LUAD, BLCA and STAD. The KIRC box plot shows higher BLOC1S4 RNA expression in tumor versus normal tissue (log2 FC = +0.655, t-test p < 0.001).
This table shows molecular features associated with BLOC1S4 in patient tissues and cancer cell lines. In patient samples, BLOC1S4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BLOC1S4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
